Research press release


Nature Communications

Drug discovery: Testing a new approach to ADHD treatment


ADHD患者は、代謝型グルタミン酸受容体(mGluR)神経伝達物質のシグナル伝達に関連する遺伝子が変異する頻度が非ADHD患者より高いことが人類遺伝学研究によって明らかになっている。そこで、Josephine Eliaたちの研究グループは、この臨床試験によってグルタミン酸作動系を標的とするADHD治療薬の効果を調べることを目指した。



A phase I clinical trial to explore the safety of a new class of drug to treat attention-deficit hyperactivity disorder (ADHD) is published this week in Nature Communications. Most drugs used to treat ADHD are stimulants that act to raise dopamine levels. An alternative line of treatment, using a non-stimulant drug, shows some potential in this small study.

Human genetic studies have shown that mutations in genes related to the neurotransmitter metabotropic glutamate receptor (mGluR) signalling occur more frequently in some individuals with ADHD than in individuals without ADHD. Thus, Josephine Elia and colleagues sought to investigate the effects of a drug that targets the glutamatergic system to treat ADHD.

The authors tested fasoracetam monohydrate (NFC-1), an activator of mGluR system that had previously been explored as a possible treatment for dementia in adults, in a small group of adolescents with ADHD. The 30 participants (20 male and 10 female) were selected from an initial cohort of 200 based on the presence of mutations in mGluR signalling related genes. The authors show that during four weeks of an escalated dose treatment regimen there were few adverse effects, and these were mostly mild. The authors also reported that the drug treatment led to clinically detectable improvements, and one parent-reported measure of behavioural improvement. These improvements were strongest in those with mutations in genes most closely related to mGluR signalling.

This study demonstrates the safety of fasoracetam in adolescents with ADHD, and suggests that using genetic approaches to classify patients with mutations in mGluR may be useful in determining which patients are most likely to benefit from this treatment.

doi: 10.1038/s41467-017-02244-2

「Nature 関連誌注目のハイライト」は、ネイチャー広報部門が報道関係者向けに作成したリリースを翻訳したものです。より正確かつ詳細な情報が必要な場合には、必ず原著論文をご覧ください。

メールマガジンリストの「Nature 関連誌今週のハイライト」にチェックをいれていただきますと、毎週最新のNature 関連誌のハイライトを皆様にお届けいたします。